Shield Therapeutics plc
STX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £17 | £16 | £10 | £7 |
| % Growth | 6.5% | 61.9% | 37.3% | – |
| Cost of Goods Sold | £9 | £9 | £5 | £6 |
| Gross Profit | £8 | £7 | £4 | £1 |
| % Margin | 46.1% | 43.1% | 45% | 14.1% |
| R&D Expenses | £1 | £1 | £1 | £1 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £12 | £13 | £15 | £16 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £1 | £0 | £0 |
| Operating Expenses | £12 | £14 | £15 | £17 |
| Operating Income | -£4 | -£7 | -£11 | -£16 |
| % Margin | -27% | -44.2% | -116.3% | -227.1% |
| Other Income/Exp. Net | -£3 | -£2 | -£1 | -£1 |
| Pre-Tax Income | -£7 | -£9 | -£12 | -£16 |
| Tax Expense | £0 | £0 | -£0 | £0 |
| Net Income | -£7 | -£9 | -£12 | -£17 |
| % Margin | -44.5% | -58.4% | -127.6% | -236.4% |
| EPS | -0.007 | -0.012 | -0.016 | -0.022 |
| % Growth | 38.8% | 25.6% | 29.7% | – |
| EPS Diluted | -0.007 | -0.012 | -0.016 | -0.022 |
| Weighted Avg Shares Out | 1,042 | 782 | 782 | 742 |
| Weighted Avg Shares Out Dil | 1,042 | 782 | 782 | 742 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £3 | £2 | £1 | £1 |
| Depreciation & Amortization | £1 | £1 | £0 | £0 |
| EBITDA | -£4 | -£6 | -£10 | -£16 |
| % Margin | -22.9% | -39.5% | -109.2% | -223.9% |